Introduction
The successes of anti-retroviral therapy (ART) are counter-balanced by their failure to completely eradicate HIV-1 infection [1] , imposing the prospect of life-long treatment still associated with potential toxicities and accumulating costs. HIV cure, consisting at best in viral eradication, or at least in a functional cure (long term control of HIV in the absence of ART), has emerged as the ultimate goal [2] [3] [4] [5] ; and has been validated with the report of an apparent cure in the "Berlin" patient [6] . Even if the concept of HIV eradication appears elusive, it has been reinforced more recently by the probable cure in the Mississippi baby case [7••] . In contrast, reaching a functional cure or remission may be more realistic and has been illustrated by the "Post-Treatment Controller" (PTC) patients [8, 9 •, 10••, 11]. PTCs durably control HIV-1 after stopping a treatment initiated at primary infection, and share some characteristics with the rare Elite Controllers (EC) [12] . These successes have opened the way for research on drugs capable of in vitro re-activation of the provirus, and to clinical trials testing novel therapeutic strategies to purge the HIV-1 reservoirs [4, 5, 13, 14, 15•, 16, 17] . However, the modest results obtained so far illustrate the major difficulties in eradicating HIV, and the need for more basic and translational research to further understand the mechanisms of HIV-1 persistence during ART, and to identify the characteristics in those rare cases of HIV "cure". This review of the recent key articles will show that even if we are not yet one step closer to HIV eradication, some recent advances have paved the way towards taking us a step closer to HIV remission.
Defining the HIV reservoirs
Understanding the sources of HIV-1 persistent reservoirs in individuals treated with combination ART (cART) is crucial in developing novel therapeutic strategies to enable elimination or durable control of the virus in the absence of treatment. The levels of HIV-1 reservoirs appears to be one of the major factors influencing the duration of virologic suppression after cessation of ART. The HIV-1 reservoirs are made up of cells containing stably-integrated, transcriptionally-silent but replication-competent proviruses, and most infected cells are memory CD4+ T cells. They can be estimated most easily by the amount of the total cell-associated HIV-1-DNA in peripheral blood mononuclear cells (PBMCs), that roughly parallels the plasma viral load (pVL) during the course of the HIV-1 infection [18, 19] , and strongly correlates with tissue viremia levels [20, 21] . In those on long term cART, the total HIV-DNA levels associated with purified total CD4+T cells are less than 1-log lower in PBMCs compared to rectal CD4 T cells [22] . The HIV-1 reservoir decrease to a much lesser extent with cART than with pVL [1] [2] [3] [4] [5] , except in some instances where cART is initiated early during acute infection [8, 19] . Other methods have been proposed to quantify HIV reservoirs. Recently a comparison was made between 11 different approaches to quantification of persistent HIV-1 infection in 30 patients on cART, using the viral outgrowth assay for resting infected CD4 T cells as a reference [23] . This study showed that PCR-based assays quantifying cells containing HIV-1 DNA demonstrated infected cell frequencies about 2 logs higher than the viral outgrowth assay; and correlated roughly with this latter assay, achieving significance for integrated HIV-1 DNA in PBMCs and HIV-1 RNA/DNA ratio in rectal CD4 T cells. However, these various methods require extensive amounts of biological material and cannot be easily applied to large cohort studies or clinical trials; while quantification of cell-associated total HIV-DNA is feasible on limited amounts of cells, and has been strongly and clinically validated for HIV diagnosis in newborns from infected mothers [20, 21] . In addition, the variations observed between the ratios of infected cell frequencies determined by viral outgrowth, and PCR-based assays among patients [23] , reflect the low quantitative reproducibility inherent to any complex function-based assay; and the presence of a large and variable pool of cells infected with defective proviruses that are not sensitive to reactivating agents [24] . A recent molecular characterization identified HIV defective viruses in 88 % of 213 non-induced proviral clones from treated patients [25••] . In addition, fulllength intact proviral clones could be reconstructed and became replicationcompetent, suggesting that the size of the latent reservoir may be up to 60-fold greater than previously estimated, based on the replication-competent viral outgrowth assay [25••] . This latter finding might reconcile the discrepancies observed between PCR-based assays and virus outgrowth assays. Two other studies showed also the accumulation of rare defective proviruses bearing APOBEC-3G signatures in various compartments [26, 27 •], i.e., PMBCs, cerebral spinal fluid, and rectal or renal tissues from 30 long-term treated chronically-infected patients [27•] . HIV hypermutated sequences were detected in 36 % of cases in at least one viral reservoir, and more often in viral sanctuaries than in peripheral blood. Altogether the accumulation of defective viruses might be falsely re-assuring if activation of replicationcompetent, non-induced viruses may occur in vivo.
Moreover, quantification of total HIV-1 DNA is considered to be integrated as a provirus in silently-infected CD4+T cells in patients with undetectable pVL [18, 19, 28] . These cells have been estimated to contain only between 1 and 2 HIV-1 provirus copies per cell [18] , thus allowing estimation of the frequency of stably infected reservoir cells. This frequency is generally low, broadly ranging from 1/100,000 to 1/100 or less, depending on the stage of infection [19] , and on the cell compartment measured. It is assumed that the CD4+T cells harbor the vast majority of those reservoirs, although monocytes and macrophages can also be infected [2-5, 19, 28, 29] . A typical hierarchy has been shown among CD4+T cells with the lowest levels observed in naïve T cells (TN), compared to the heterogeneous memory CD4+T cell compartment, composed of the central memory (TCM), transitional memory (TTM), and effector memory (TEM) CD4+T cells [10••, 28-31] . Levels of infection also differ whether they are measured only in quiescent resting CD4+T cells, or in mixtures of activated and quiescent T cells. Heterogeneous levels of HIV-1 persistence among CD4+T cell subsets appear to reflect a composite of low-level virus production and persistence of latent integrated proviruses, two mechanisms that are strongly influenced by the heterogeneity in CD4+T cell subset homeostasis, activation and turn-over; while reservoir clearance depends upon cell death or recognition by the immune system [5, 6, 10••, 28, 29, 32••]. These mechanisms might also be influenced by host-related factors and the patient's "history" of HIV-1 infection, such as duration of HIV-1 infection prior to ART initiation and CD4 nadir, suboptimal intracellular penetration of the potent modern ART, and duration of viral suppression, as well as residual immune activation among sufficiently treated patients [33] ; although such an hypothesis has not yet been proven. Besides anatomical sanctuaries, HIV-1 reservoirs are thought to be preserved through HIV-1 DNA persistence in quiescent cells, and cycles of residual viral repli-cation arising from viral reactivation in latently-infected cells exposed to antigenic and homeostatic stimuli in an uncontrolled pro-inflammatory environment.
Barriers to an HIV cure
Persistence of true (i.e., non-defective) HIV-1 latency represents certainly the biggest challenge to finding a cure for HIV [2] [3] [4] [5] , and depends mainly upon mechanisms inducing post-integration latency. Multiple viral and cellular factors have been described so far, but it is unclear which are the most efficient at preventing effective proviral transcription in patients' host cell genomes, allowing some HIV-1-infected CD4+ T cells to survive and revert to a resting memory state. In addition, most of these mechanisms have been defined in cell lines and cellular models of latency, but remain poorly defined in primary cells from treated patients.
HIV-1 itself manipulates its target cells to convert them into effective virus producers, rather than carriers of transcriptionally silent proviruses. The early and late regulatory proteins (Nef and Vpu) affect control of HIV-1 transcription by modulating the key NF-κB host transcription factor [34, 35] . Control and repression of HIV-1 transcription is certainly crucial to the establishment and maintenance of post-integration latency [3, 4] . HIV transcription is known to be controlled at various levels: i) site of integration and mechanisms of transcriptional interference; ii) inducible host transcription factors and transcriptional repressors; iii) nucleosomal organization of the HIV-1 promoter; iv) epigenetic level including histone posttranslational modifications and DNA methylation; v) positive-transcription-elongationfactor-b (P-TEFb) [36] [37] [38] [39] [40] [41] [42] . The involvement of these elements in post-integration latency, particularly the epigenetic modifications, certainly depends on the status of activation and differentiation of the heterogeneous CD4+ T cell subsets hosting the HIV-1 reservoirs, but these aspects have not been defined in patients on cART. In vitro, cellular activation has resulted in the expression of cell restriction factors capable of suppressing HIV replication with an increase interferon-stimulated genes such as ISG15, but also the wellknown HIV restriction factors TRIM5, tetherin, and some APOBEC3 family members [43] . Other Type-I interferon stimulated genes (ISG) also seem to play a key role in the innate immune response against HIV, such as Schlafen-11 (SLFN11), an ISG and restriction factor which acts by down-modulating HIV-1 mRNA translation [44] , and is found to be elevated in CD4+T cells from Elite Controllers (EC), compared to viremic and treated patients. These findings suggest that SLFN11 may play a role in the suppression of HIV-1 in vivo [45] . Another protein, 90 K, has recently been described as an antiviral factor associated with the release of poorly infectious virion, and induces defective maturation of HIV-1 Env during the novo virus production, and reduced incorporation of Env into progeny virions [46] . Finally, the Myxovirus-resistance-2 molecule (MX2) has recently been demonstrated to be an IFN-induced inhibitor of HIV-1 infection by probably inhibiting capsid-dependent nuclear import of subviral complexes [47] . In addition, the RNAassociated early-stage anti-viral factor (REAF) has been reported to block HIV and SIV at an early post-entry stage during or following initiation of reverse transcription [48] . The cyclin-dependent kinase inhibitor p21 (CIP1/WAF1) also impairs HIV/SIV reverse transcription in macrophages [49, 50] . These factors acting in the early stages of viral replication might reduce HIV-1 provirus integration, thus further limiting the size of HIV reservoirs.
Overall, these pathways illustrate the multiple challenges in HIV eradication and require a better understanding of how the mechanisms operate in optimally-treated patients. The pleiotropic mechanisms involved also show that designing future therapeutic strategies to eliminate latent HIV-1 infection, or to restrict the latent pool to a size that the host immune system can control, might require a combination of approaches.
One step closer to therapeutic strategies towards a cure?
Despite these multiple barriers to an HIV cure and the complex pathogenetic mechanisms involved, two broad clinical strategies are currently being proposed to purge HIV reservoirs; either by limiting further the residual replication, or by activating virus production from the latent compartment. Although still far from an ideal goal, strategies based upon very early initiation of cART have recently shown some very promising, though debatable results.
Therapeutic strategies to limit residual HIV production

Early ART initiation and HIV cure of the Mississippi baby
This second highly publicized case of an apparent cure of HIV was announced last year at CROI. It is as appealing as the "Berlin patient", though much simpler and more practical with the use of conventional ART regimen. The innovation seems to lie in the very early initiation of cART, only 31 hours after the newborn's delivery from an untreated mother who was diagnosed with HIV at delivery with a moderate pVL below 2,500 copies/ mL, and normal CD4 counts [7••] . The infant's pVL rapidly became undetectable and remained so during the 18 months of cART, as well as during the 18 months after ART interruption, with only traces of HIV; DNA in PBMC at month 26 confirmed that the baby had truly been infected. The extended follow-up of this child will tell us whether this is the second known eradication of HIV or simply a functional cure.
What can we learn from this case? Firstly, that a very early cART intervention within the first day after delivery might interfere with the establishment of a persistent reservoir. Secondly, that this case may perhaps not be that exceptional. Since its disclosure, all pediatricians following HIV-infected children treated at birth have initiated studies evaluating the size of HIV reservoirs in those children, and some ART interruption studies in highly selected children are likely to be performed.
The Post-Treatment Controllers (PTC) from the Visconti study
A few HIV patients, diagnosed early in primary infection and started on cART almost immediately and for a prolonged period, were able to durably control viremia after treatment interruption. This key population has been compared to standard non-controller patients and to the rare Elite Controllers. PTCs display a symptomatic primary infection, with pVL and CD4+T cell counts comparable to non-controller patients, and represent from 8 % to 15 % of early-treated patients [9•, 10••]. Genetic analysis indicates an enrichment of some HLA-class I molecules in PTCs such as HLA B*07 and B*35 (associated with accelerated progression to AIDS), but no increase in the protective HLA B*27 or B*57 like in Elite Controllers [10••] . Accordingly the PTCs anti-HIV CD8+T cells frequency and suppressive capacity are lower than in ECs, with less activated total CD8+T cells, which suggests that CD8+T cell responses might not be implicated in viral control in those PTCs. The early treatment could favor the spontaneous control of the infection by limiting the establishment of viral reservoirs [51] , and the diversity of the virus [52, 53] , as well as the immune alterations [54, 55] ; three conditions that could facilitate later control by undamaged immune responses. Along these lines, PTCs display a very small viral reservoir comparable to ECs, particularly in the long-lived naïve and central-memory CD4+T cells [9•]. Interestingly, during the follow-up, the viral reservoirs were shown to shrink over time in some PTCs. This encouraging PTC phenomenon suggests that limiting the number of infected cells early after infection is crucial for the maintenance of viral control in the absence of therapy. Nevertheless, more investigation is needed to understand the mechanisms of viral control in these peculiar patients.
ART intensification
The concept of treatment intensification has been supported by cART pharmacodynamic limitations. It is crucial to have constant optimal concentrations of antiretroviral drugs in compartments such as in lymph nodes or the central nervous system, where concentrations of some widely used drugs are far from optimal. Most cART intensification strategies utilized the integrase inhibitor raltegravir, either alone or in combination, and have been shown in some reports to increase production of 2-LTR circles, suggesting an impact on the residual HIV production [14, 56] . More recently, a small study reported that a combination of an early integrase inhibitor-based treatment with an entry inhibitor such as maraviroc resulted not only in a faster reduction of 2-LTRs in newly infected cells and a faster CD4+T cell recovery, but also in a modest reduction in total reservoir size after 48 weeks of treatment [57] . However, a larger randomized clinical trial did not confirm the benefits of a similar treatment intensification initiated within a month after infection, compared to a standard triple Cart [58] . Similar disappointing results of a dual intensification strategy have been reported after a 48 week intensification in chronically-infected patients [17] .
Strategies repressing HIV transcription and production
Even in optimally-treated HIV-infection, chronic immune activation can persist, with pro-inflammatory cytokines, IFN-α production, and increased frequencies of activated CD4+T cells, and may contribute to a continuous low level (although "undetectable") virus production. Some strategies targeting inflammation have been proposed, such as drugs blocking type I Interferons, or the PD-1-PDL interactions that enhance innate and specific immunity [4, 5] . Another option might be to use agents interfering with some tyrosine-kinase (TK) activation pathways, such as inhibitors (TKIs) of intracellular tyrosine-kinases known to be well tolerated when chronically administered. This is the logic for Dasatinib and Imatinib, ABL tyrosine-kinase inhibitors (TKIs) used in treatment of chronic myelogenous leukemia and considered for use in inflammatory diseases. While the HIV-1-cell fusion process depends also on the TK ABL, TKIs can block in vitro Env-mediated cell-cell fusion and virus-cell fusion in cell lines. Our group recently showed that Dasatinib could block in vitro HIV production in primary CD4+T cells from HIV-infected patients by inhibiting cell activation and proliferation, without inducing cell death; while the most commonly used drug Imatimib was too toxic for T cells [59] . The good safety profile of Dasatinib and the ability of this molecule to hinder persistent immune-activation and residual viral production should be further investigated in vivo for inclusion in strategies for HIV cure.
Finally, while administration of strong immunosuppressive drugs in HIVinfected patients is feasible and necessary (as in transplanted HIV-infected patients), increasing immunosuppression in patients at high risk of immunodeficiency in case of cART interruption is an issue. Testing first whether these immunosuppressive agents help to decrease viral reservoirs in nonhuman primate animal models might be a valid option before translation into clinical trials.
Purge strategies targeting HIV latency with HDAC or IL-7
Finally "flushing out" procedures have been proposed as an option to try purging the HIV reservoirs by de-repressing HIV-1 gene expression, and reverting the transcriptional silence lying at the core of HIV-1 proviral persistence in latently-infected cells [2, 36, 37, 60] .
Histone de-acetylase (HDAC) inhibitors and other classes of epigenetic modifiers
The most commonly tested agents are the HDAC inhibitors, particularly vorinostat which promotes histone acetylation and is used for treatment of cutaneous T cell lymphoma. Culture of latently infected cells with this drug in vitro induces a significant modest increase in HIV-1 transcription and/or production, depending on the cellular model used, and usually far below the level induced by classical activation pathways [61] [62] [63] . Two pilot clinical trials tested vorinostat, one using a single dose [15] , and the other a repeated dose for 14 days (NCT01365065) [16] . Although controversial, both trials showed some enhancement in HIV-1 transcription in vivo, particularly after repeated doses of vorinostat; but neither succeeded at reducing the levels of the HIV-1 reservoirs. Another, more potent HDACi, parabinostat, is currently being tested in a clinical trial (NCT01680094) [64] . While more selective class I HDAC inhibitors such as entinostat might be even more attractive, this has not yet been tested in vivo [65] .
Other epigenetic strategies might be proposed by targeting the hypermethylation of the HIV-1 promoter shown in some long-term cART-treated aviremic individuals [61] , although this is still being debated [25••] . Accordingly some Histone-Methyl-Transferase (HMT) inhibitors yield in vitro results roughly comparable to the HDACi [61, 62] ; while classical HMT inhibitors, such as 5-Azacytidine or decitabine, two well-tolerated drugs used for decades in other indications, have been proposed for in vivo trials [4, 5, 16, 66•] . However a two week administration of decitabine failed at reducing the size of the HIV reservoirs in fully suppressed cART treated patients [66•] .
Interleukin-7
Another purging candidate was interleukin-7 (IL-7), a human cytokine targeting the Stat-5 and Akt pathways and involved in intra-thymic T cell differentiation and homeostatic proliferation of mature T cells. This cytokine was shown to increase in vitro transcription and production of HIV provirus by many groups, including our own [2, 10••, 29, 66•, 67-69]; although others have failed to demonstrate generation of virus diversity [28] . This cytokine had been used in vivo for its proliferative homeostatic activity to augment CD4+T cell counts, and displayed a good clinical safety profile, despite some transient "blips" of plasma viremia in patients on conventional ART [69] . Our group therefore conducted a clinical trial, the ERAMUNE-01 study, to investigate in chronically-infected patients with suppressed HIV viremia, the capacity of interleukin-7 plus a dual intensification strategy with raltegravir/ maraviroc, or intensification alone, to decrease the HIV reservoirs [17] . However, as with HDACi or decitabine, results were disappointing and demonstrated that this cytokine was inefficient at disrupting HIV latency and at purging the HIV reservoirs.
Thus, none of those "purging" strategies have succeeded in reducing the HIV reservoirs so far, suggesting that the targeted mechanisms were not the only ones responsible for HIV persistence in vivo. Furthermore, a recent comparison of thirteen stimuli reactivating HIV by defined mechanisms of action (including HDAC Inhibitors and IL-7), showed very discordant results in several culture models, including latent primary T cell models, latent T cell lines and infected patients primary T cells [63] . These results, as others [10••, 29] , indicate that the activation and differentiation status of the reservoir cells determine the mechanisms involved in HIV latency, and the various cell sensitivity to these stimuli. Thus barriers to HIV eradication are more diverse than initially thought.
So far, only the early treatment initiation has brought us one step closer to HIV eradication, with at the best the cure of the Mississipi baby, and at the least the functional cure of the PTC cohort. Whether these successes are exceptional, and early cART initiation the only explanation for inducing PTCs, or whether this goal is achievable in patients treated during the chronic phase, remain key questions currently under investigation in our group. Altogether these results are encouraging enough to continue exploration of the concept by defining novel, alternative, or complementary strategies targeting the mechanisms of HIV-1 repression listed above. While no strategy aimed at purging the reservoir has yet been successful, this should not discourage continuing research to further understand the main obstacles towards HIV eradication. Ultimately, the strategy chosen should be dictated by the predominant mechanisms in CD4+T cells from the patients eligible for these innovative therapeutic strategies. Meanwhile, one of the major lessons in recent years is that early initiation of antiretroviral therapy is the best way to preserve immune cells, limit viral reservoirs, prevent deleterious immune activation, and inflammation from uncontrolled HIV viremia.
The massive research efforts in the 1990s led to major progress in therapy. Significant advances in our knowledge of the mechanisms of HIV persistence will undoubtedly come from basic, translational, and clinical research. The most frequent wish from patients remains "Doctor, when will we be able to stop therapy?"
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